VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has provided an update on its strategy to implement U.S. Food and Drug Administration (FDA)-aligned New Approach Methodologies (NAMs) across its preclinical research and development programs. The company said the approach could accelerate clinical advancement, reduce development costs and timelines, and significantly reduce animal testing.
VERAXA has built a panel of NAMs to characterize and de-risk its pipeline of BiTAC-based T cell engagers, antibody-drug conjugates, and bispecific antibody-drug conjugates. According to the company, its lead BiTAC-TCE and bsADC candidates were evaluated using an ex vivo panel of 10 low-passage patient-derived xenograft models of non-small cell lung cancer. This panel required about 10 mice in total, compared with an estimated 200 or more for comparable in vivo efficacy studies. Across the panel, the combined BiTAC consistently induced potent T cell-mediated killing, supporting the company's dual-targeting approach and demonstrating how its NAM strategy can reduce animal use and preclinical cycle time without compromising clinical relevance.
The implications of this announcement are significant for both the biotechnology industry and investors. By aligning with FDA's evolving stance on alternatives to animal testing, VERAXA is positioning itself at the forefront of a regulatory shift that could streamline drug development. The reduction in animal use addresses growing ethical concerns and may also lower costs and shorten timelines, potentially bringing therapies to patients faster. For a company like VERAXA, which is advancing a pipeline of complex antibody-based therapeutics, these efficiencies could provide a competitive edge in a crowded oncology landscape.
Investors can stay updated on VERAXA's progress through its newsroom at http://ibn.fm/VRXA. The full press release is available at https://ibn.fm/9YRJw. For more information about VERAXA Biotech, visit VERAXA Biotech (NASDAQ: VRXA).
BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors, is one of more than 75 brands within the Dynamic Brand Portfolio at IBN. The platform delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution to millions of followers, and a full array of tailored corporate communications solutions. For more information, visit www.BioMedWire.com. Full terms of use and disclaimers are available at https://www.BioMedWire.com/Disclaimer.
